Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n=93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n=46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n=95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P<0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.
Yeh
Chen-Hsiung
CH
Department of Hematopathology, 33608 Ortega Highway, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA 92690, United States.
Tseng
Richard
R
Zhang
Zhong
Z
Cortes
Jorge
J
O'Brien
Susan
S
Giles
Francis
F
Hannah
Alison
A
Estrov
Zeev
Z
Keating
Michael
M
Kantarjian
Hagop
H
Albitar
Maher
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D015415:Biomarkers / Q000097:blood; D018450:Disease Progression; D018840:HSP70 Heat-Shock Proteins / Q000097:blood*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis*; D015465:Leukemia, Myeloid, Accelerated Phase / Q000175:diagnosis; D015466:Leukemia, Myeloid, Chronic-Phase / Q000175:diagnosis; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D055815:Young Adult
D001549:Benzamides; D015415:Biomarkers; D018840:HSP70 Heat-Shock Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate